SCHEDULE: Casdin Capital Divests Entire Codexis Stake

Casdin Capital and its affiliates have filed an amended Schedule 13G, reporting a complete divestment of their beneficial ownership in Codexis, Inc. common stock.

Summary

• Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, and Eli Casdin have filed an Amendment No. 2 to Schedule 13G regarding their holdings in Codexis, Inc.
• As of September 30, 2025, the reporting persons beneficially own 0 shares of Codexis, Inc. common stock, representing 0% of the class of securities.
• This filing indicates a complete divestment of their previous stake in Codexis, Inc.
• The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing the control of Codexis, Inc.

Sentiment

Score: 2

Explanation: The complete divestment by a significant institutional investor like Casdin Capital is a strong negative signal, suggesting a lack of confidence in the company's future prospects. While the filing itself is routine for reporting ownership changes, the underlying action of selling off an entire stake is bearish.

Negatives

• Casdin Capital and its affiliates have divested their entire beneficial ownership in Codexis, Inc., reducing their stake to 0%.
• This complete divestment by a significant institutional investor could be perceived negatively by the market, potentially signaling a loss of confidence.

Risks

• The complete divestment by Casdin Capital, a prominent life sciences investor, might signal a loss of confidence in Codexis, Inc.'s future prospects.
• Such a significant reduction in institutional ownership could lead to increased stock volatility or downward pressure on the share price.

Future Outlook

No forward-looking statements or guidance from Codexis management are provided in this filing. The reporting persons certified their intent regarding control of the issuer.

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
• "Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."

Industry Context

Casdin Capital is a well-known investor in the life sciences and biotechnology sectors. Their complete exit from Codexis could be interpreted within the broader context of investor sentiment towards specific biotech sub-sectors or individual company performance, potentially signaling a shift in investment strategy or outlook for Codexis within the industry.

Stakeholder Impact

• Shareholders: Existing shareholders may react negatively to the news of a major institutional investor divesting its entire stake, potentially leading to downward pressure on the stock price.
• Management: May face questions regarding the reasons for the divestment and its implications for investor confidence.

Key Dates

Recommendation

The complete divestment of Casdin Capital's entire beneficial ownership in Codexis, Inc. to 0% is a significant bearish indicator. Institutional exits of this magnitude often precede or accompany periods of underperformance or reflect a loss of conviction in the company's strategic direction or financial prospects. While the filing itself is a regulatory requirement, the underlying action of selling off an entire position by a sophisticated investor warrants a 'sell' recommendation, as it suggests a material negative re-evaluation of the investment.

Keywords

Codexis Inc, CDXS, Casdin Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Divestment, Equity Stake, SEC Filing